Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 71

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 71
---
 as the investment manager to NTE and NP, may be deemed to beneficially own these securities. Accordingly, as of December 31, 2024, Newtyn Management may be deemed to beneficially own the 4,757,403 shares held in the aggregate by NTE and NP. NTE has sole voting and dispositive power over 2,902,002 shares and Newtyn Management has sole voting and dispositive power over 4,757,403 shares. (5) Based on the Form 13F filed with the SEC on February 7, 2025 by BlackRock, Inc. (“Blackrock”). Blackrock has sole voting power of 3,563,577 shares and sole dispositive power of 3,712,303 shares. The subsidiaries included in the report were as follows: Blackrock Financial Management Inc/DE, BlackRock Investment Management (Australia) Ltd, BlackRock Asset Management Canada Ltd, BlackRock Investment Management, LLC, Blackrock Advisors LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Fund Managers Ltd., BlackRock Investment Management (UK) Ltd., BlackRock (Netherlands) B.V., BlackRock Asset Management Ireland Ltd, BlackRock (Luxembourg) S.A., BlackRock Asset Management Schweiz AG, and Aperio Group, LLC. (6) Based on Schedule 13G filed with the SEC on February 14, 2024 by Irenic Capital Management LP (“Irenic Capital”), Irenic Capital Evergreen Master Fund LP (“Irenic Evergreen Master Fund”), Adam Katz, and Andrew Dodge, with respect to shares held by Irenic Evergreen Master Fund. Irenic Capital, Irenic Evergreen Master Fund and Messrs. Katz and Dodge each has shared voting and dispositive

46

TABLE OF CONTENTS power of 2,760,948 shares. Irenic Capital is the investment manager of Irenic Evergreen Master Fund. Irenic Capital Management GP LLC (“Irenic Capital GP”) is the general partner of Irenic Capital. Irenic Capital Evergreen Fund GP LLC (“Irenic Evergreen GP”) is the general partner of Irenic Evergreen Master Fund. Adam Katz is the Chief Investment Officer of Irenic Capital and a managing member of each of Irenic Capital GP and Irenic Evergreen GP. Andrew Dodge is the Director of Research of Irenic Capital and a managing member of each